|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Angiogenesis and antiangiogenic therapy显示文摘 | Miller K D | 2002 | Curr ProblCaacer2002，26，1： | 1 |
| 2 | Exploiting the hallmarks of cancer: the future conquest of breast cancer显示文摘 | Sledge G Miller K | 2003 | Eur J Cancer2003，39，12： | 1 |
| 3 | Phase Ⅲ trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as first- line therapy for metastatic cancer: an intergroup trial显示文摘 | Sledge G N Neuberg D Ingle S | 1997 | J Clin Oncol1997，16，： | 1 |
| 4 | Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production显示文摘 | Starnes T Robertson MJ Sledge G | 2001 | J Immunol2001，167，8： | 1 |
| 5 | Phase Ⅲ trial of doxo- rubicin, paclitaxel, and the combination of doxorubicin and pacli- taxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (El193) 显示文摘 | Sledge G Neuberg D Bermardo P | 2003 | J Clin Oncol2003，21，4： | 1 |
| 6 | Exploiting the hallmarks of cancer: the future conquest of breast cancer显示文摘 | Miller K | 2003 | Eur J Cancer2003，39，12： | 1 |
| 7 | Cispla- tin as frst-line therapy for metastatic breast cancer 显示文摘 | SLEDGE G W Jr LOEHRER P J St ROTH B J | 1988 | J Clin Oncol1988，6，12： | 1 |
| 8 | Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production 显示文摘 | Starnes T Robertson M J Sledge G | 2001 | J Immunol2001，167，8： | 1 |
| 9 | Redefining the target:chemotherapeutics as antiangiogenics显示文摘 | Miller K D Sweeney C J Sledge G W Jr | 2001 | J Clin Oncol2001，19，4： | 1 |
| 10 | Making personalized cancer medicine a reality:challenges and op- portunities in the development of biomarkers and companion diagnostics 显示文摘 | Parkinson D R Johnson B E Sledge G W | 2012 | Clinical Cancer Research2012，18，3： | 1 |
| 11 | Cutting edge: IL-17F,a novel cytokine selectively expressed in activated T cells and monocytes,regulates angiogenesis and endothelial cell cytokine production 显示文摘 | Statues T Robertson M Sledge G | 2001 | J Immunol2001，167，8： | 1 |
| 12 | A phase Ⅰ/ Ⅱ dose - escalation trial of bevaeizumab in previously treated metastatic breast cancer 显示文摘 | COBLEIGH M A LANGMUIR V K SLEDGE G W | 2003 | Semin Oncol2003，30，16： | 1 |
| 13 | Association of polymorphisms of angiogenesis genes with breast cancer显示文摘 | Schneider B P Radovich M Sledge G W | 2008 | Breast Cancer Res Treat2008，111，1： | 1 |
| 14 | Cisplatin as firstline therapy for metastatic breast cancer 显示文摘 | Sledge G W Jr Loehrer P J Sr Roth B J | 1988 | J Clin Oncol1988，6，12： | 1 |
| 15 | Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and mono- eytes, regulates angiogenesis and endothelial cell eytokine produc- tion显示文摘 | Statues T Robertson MJ Sledge G | 2001 | J lmmunol2001，167，41： | 1 |
| 16 | Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T ceils and monocytes, regulates angiogenesis and endothelial cell cytokine pro- duction显示文摘 | STARNES T ROBERTSON M J SLEDGE G | 2001 | J Immunol2001，167，8： | 1 |
| 17 | Medicago truncatula ESTSSRs reveal cross-species genetic markers for Medicago spp显示文摘 | Sledge M K Wang L May G D Chekhovskiy K Zwonitzer J C Mian M A R | 2004 | Theor Appl Genet2004，108，3： | 1 |
| 18 | Redefining the target:chemotherapeutics as antiangi0genics显示文摘 | Miller K D Sweeney C J Sledge G W | 2001 | J Clin Oncol2001，19，4： | 1 |
| 19 | Cutting edge:IL 17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cellcytokine production 显示文摘 | Starnes T Robertson M Sledge G | 2001 | J Immunol2001，167，： | 1 |
| 20 | Doxorybincin/pacltaxel combination chemotherapy for metastatic breast cancer: the Easten cooperative Oncolgy Group experience显示文摘 | Sledge G W Jr | 2003 | Sermin Oncol2003，22，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员